Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 131

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 131
---
 all of our sales being made in Argentina, it also includes international customers from a variety of geographic markets in Latin America and elsewhere. As part of our strategy, we aim to increase our volume of direct sales to international customers in a variety of markets by conducting targeted marketing outreach activities and, if opportunities arise, engaging distributors or establishing other types of arrangements, such as additional joint ventures or other relationships. However, we may never be successful in achieving these objectives, and even if we are successful, these strategies may not result in meaningful or any increases in our customer base, test volumes or revenue. Doing business internationally involves a number of risks, including, among others: •compliance with the laws and regulations of multiple jurisdictions, which may be conflicting or subject to increasing stringency or other changes, including privacy and data protection regulations, tax laws, employment laws, healthcare regulatory requirements, and other related approvals, including permitting and licensing requirements; •logistics associated with the shipment of blood, saliva, stool or tissue samples, including infrastructure conditions, transportation delays, and the impact of local laws and regulations, such as export and import restrictions, tariffs, or other charges and other trade barriers, all of which involve increased risk related to the trade policies of a jurisdiction’s current administration, which may threaten existing and proposed trade agreements and impose more restrictive export -importregulations that impact our business; •limits on our ability to penetrate international markets, including legal and regulatory requirements that would force us to conduct our tests locally by building additional laboratories or engaging in joint ventures or other relationships in order to offer our tests in certain countries, which relationships could involve significant time and resources to establish, deny us control over certain aspects of the foreign operations, or reduce the economic value to us of these operations; •failure by us, any joint venturers, or other arrangements we have or may establish, or by any distributors or other commercial partners we have engaged or may engage to obtain any regulatory approvals required to market, sell, and use our tests in various countries; 41 •challenges predicting the market for our tests and services generally and tailoring our services to meet varying customer expectations in different countries and jurisdictions; •difficulties gaining market share in jurisdictions in which we do not have a strong physical presence or brand awareness; •complexities and difficulties obtaining protection for and enforcing our intellectual property rights; •difficulties in staffing and managing foreign operations and the increased travel, infrastructure and legal compliance costs associated with multiple international locations and subsidiaries; •complexities associated with managing multiple payor